Oxford Pharmascience appoints Karl Van Horn to Board as independent Non-Executive Director

– UK – Oxford Pharmascience (AIM: OXP), the speciality pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces the appointment of Karl Robertson Van Horn, aged 79, to its Board of Directors.

Mr Van Horn has had a distinguished multinational career in senior positions across investment management, corporate governance, industry and not-for-profit organisations. He has held senior roles in the Trusts and Investments Division of The Morgan Guaranty Trust, American Express Asset Management, the Qatar Investment Board (Doha), J.P. Morgan (Japan) and Aspcomp (Helsinki) amongst other institutional mandates.

Mr Van Horn is currently the Chairman of the Taube Offshore Fund (Cayman) and a director of American Express Asset Management N.V. (although he has had no active involvement with the latter since 1987). He also is a member of the Investment Management Institute (New York), a Life Trustee of University School (Cleveland, Ohio) and a Trustee of the University of Bologna (Italy).  Mr. Van Horn holds a Doctorate in International Affairs from Bologna/Johns Hopkins, a MA in Economics from Cambridge University and a BSc from Yale University.  He was formerly a director of Front Row Partners UK LLP.

Commenting on the appointment, Dave Norwood, Non-Executive Chairman of Oxford Pharmascience, said: “We welcome Karl Van Horn to the Board as an independent non-executive director. His international experience in stakeholder relations and organisational governance bring valuable skills and diversity of thought to the Board as Oxford Pharmascience develops globally in all phases of its activities.”

 Commenting on his appointment, Karl Van Horn said: “I am pleased to join the Board of Oxford Pharmascience and I look forward to applying my experience in assisting the future development of the Company.”

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.